1. Introduction {#sec1}
===============

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by degeneration of the brain and spinal cord leading to weakness, wasting, bulbar problems, and usually death within 3 years ([@bib6]). Originally noted in an essay in 1830 by Charles Bell the disorder has been described throughout the world with an ALS incidence of between 1.7 and 8.2 people per 100,000 in populations in Europe and the United States, the lowest incidence being in Italy (Turin) ([@bib17]) and highest in Finland ([@bib2; @bib8; @bib18; @bib21]). Approximately 10% of ALS cases are familial, and genetic defects have been identified in approximately a third of families ([@bib26; @bib30; @bib32]) and a small percentage of sporadic cases, in an ever-increasing number of genes that include: superoxide dismutase 1 (*SOD1*) ([@bib27]), transactivation response (TAR) DNA binding protein (*TARDBP*) ([@bib28]), fused in sarcoma (*FUS*) ([@bib15]), valosin-containing protein (*VCP*) ([@bib14]), factor-induced gene 4 (*FIG4*) ([@bib5]), angiogenin (*ANG*) ([@bib12]), ubiquillin *2* (*UBQLN2*) ([@bib10]), and optineurin (*OPTN*) ([@bib19]).

More than 10 years ago, a locus for autosomal dominant familial ALS and frontotemporal dementia was identified on chromosome 9p21 ([@bib20]). This region was refined to a common 140 kb haplotype containing 3 genes, *MOBKL2B*, *C9orf72*, and *IFNK* that were extensively investigated ([@bib16; @bib31]). Two research groups identified a pathogenic GGGGCC hexanucleotide repeat expansion in intron-1 of the *C9ORF72* gene as an important cause for both familial and sporadic ALS ([@bib9; @bib25]). They found the expansion (greater than 30 repeats) was present in 46.4% of familial ALS and 21% of sporadic ALS cases from Finland and between 28.5% and 38% familial ALS in series from Italy, Germany, and the United States ([@bib22]). The expanded repeat was absent in US, Italian, and German controls but present at a rate of 0.4% in Finnish controls. In the UK, pathological expansions accounted for 50% (26/52) of familial and 7% (35/496) of sporadic ALS ([@bib7]). Further analysis of the incidence in sporadic ALS suggests a marked difference across Europe (north to south), the highest prevalence being in Finland (21.1%), then the UK (7%), then Germany (5.2%), Belgium (5%), and the lowest in Italy at 4.1% ([@bib7; @bib9; @bib11; @bib25]; Traynor, B.J., personal communication, *C9ORF72* hexanucleotide repeat expansion in sporadic ALS and FTD around the world, 2012). Sardinia is likely to have a higher prevalence, but this is an unusual isolated population which also contains a high frequency of *TARDBP* mutations ([@bib4]). The overall incidence of ALS may suggest a founder expansion, disseminated by a traveling population such as the Vikings or it could be accounted for by population-specific effects such as isolation. Clinically, the *C9ORF72* expansion causes a frontotemporal dementia (FTD), and an ALS with phenotype is often associated with cognitive problems compared with unexpanded patients. Neuropathologically, abnormal subcellular localization and aggregation of TAR DNA binding protein 43 (TDP-43) is found widely distributed in most patients with ALS and FTD, cortical lesions are TDP-43 positive but cerebellar lesions are negative ([@bib1; @bib13; @bib29]). These findings further highlight the importance of TDP-43 in FTD and ALS.

There are no further data available on the frequency and phenotype of *C9ORF72* expansions in other European or Mediterranean populations. We therefore examined the frequency, spectrum, and phenotype of patients with an expanded *C9ORF72* hexanucleotide repeat in a well-defined series of ALS cases and controls from Greece.

2. Methods {#sec2}
==========

DNA was extracted from 146 ALS cases and 228 controls consecutively collected from the Neurology Department of the University of Athens, Greece. The study was ethically approved with informed consent from patients taking part who were diagnosed according to the El Escorial criteria ([@bib3]). We screened the *C9ORF72* GGGGCC expansion in the ALS cohort and the controls using the reversed-prime polymerase chain reaction (PCR) protocol as previously reported ([@bib25]). Briefly, 100 ng of genomic DNA was amplified with a final volume of 20 μL containing 10 μL FastStart PCR Master-Mix (Roche, Foster City, CA, USA), 0.18 mM 7-deaza dGTP, 1xQiagenQ solution, 10% dimethyl sulfoxide (DMSO), 0.7 μM reverse primer consisting of 4 GGGGCC repeats and an anchor tail (TACGCATCCCAGTTTGAGACGGGGGCCGGGGCCGGGGCCGGGG), 1.4 μM 6FAM-fluorescent-primer located 280 base pairs 3′ prime to the repeat sequence (AGTCGCTAGAGGCGAAAGC) and 1.4 μM anchor primer corresponding to the anchor tail of the reverse primer (TACGCATCCCAGTTTGAGACG). A touchdown PCR cycling protocol was used where the initial annealing temperature was lowered from 70 °C to 56 °C in 2 °C increments and a 3-minute extension time for each cycle ([@bib24]). Fragment length analysis was performed on an ABI 3730XL genetic analyzer (Applied Biosystems, Inc., Foster City, CA, USA), analyzed using ABI GeneScan v 3.7 (Applied Biosystems, Inc., Foster City, CA, USA).

3. Results {#sec3}
==========

Overall, 10.95% (*n* = 16) of ALS cases carried the *C9ORF72* pathological expansion (defined as \> 30 repeats). In the 146 ALS cases, 10 were familial ALS probands, 50% (*n* = 5) of them carried a pathologically large expansion. In the remaining 136 sporadic ALS, 11 were carriers (8.2%) ([Table 1](#tbl1){ref-type="table"}). There was no significant difference in gender, age, and age/site of onset between expansion carriers and noncarriers; there was also no significant difference in the age of onset between patients with and without expansions ([Table 1](#tbl1){ref-type="table"}, [Fig. 1](#fig1){ref-type="fig"}). No expansions were seen in controls. The cumulative frequency on the age of onset suggested that penetrance is about 50% at 55 years old and almost complete penetrance at 75 ([Fig. 1](#fig1){ref-type="fig"}). The phenotype of the familial and sporadic ALS cases was either spinal upper or lower limb onset (13/16) or bulbar (3/16) onset, the age of onset ranged between 25 and 73 years. In familial ALS, there were no bulbar onset cases and a greater preponderance of female cases ([Table 1](#tbl1){ref-type="table"} and [Supplementary Table 1](#sec7){ref-type="sec"}).

4. Discussion {#sec4}
=============

The identification of *C9ORF72* expansions in ALS and FTD has been an extremely important discovery that will form an essential common diagnostic test in ALS and FTD and also strengthen the link to TDP-43 ([@bib22]). We report the prevalence of the *C9ORF72* repeat expansion in a cohort of Greek ALS patients revealing a relatively high prevalence of expanded repeats in the Greek sporadic ALS population (8.2%). This is the highest sporadic figure outside of Finland reported to date. These data support the pathological expansion as an important cause of ALS that extends to Mediterranean populations. A further interesting point is that the majority of Greek cases with expansions have a spinal onset, much higher than in the previous reports where the proportion of bulbar onset cases was much higher ([@bib9; @bib25]).

The 50% prevalence of the expansion within Greek familial ALS is congruent with previous reports. Previously we have reported the likely common founder effect originating from Scandinavia. Haplotypes in the ALS cases from other populations (USA and Italy) also carry part of the Finnish haplotype and it would be extremely interesting to further define the haplotype that harbors the mutation in the Greek population. The high frequency of expansions in the Greek population is not consistent with the reported decreasing frequency of expanded repeats in ALS when traveling south across Europe where frequencies consist of Finland (21.1%), UK (7%), Germany (5.2%), Belgium (5%), and Italy at 4.1% ([@bib7; @bib9; @bib11; @bib25]; Traynor, B.J., personal communication, *C9ORF72* hexanucleotide repeat expansion in sporadic ALS and FTD around the world, 2012). These frequencies are similar to the overall distribution of ALS in these countries. It has been suggested the ALS haplotype could be accounted for by the Vikings, but Viking influence was limited in Greece. A more plausible explanation is the relatively isolated nature of the Greek population over recent centuries with low values of past and present racial admixture. This explanation may underlie the high frequency of the ALS haplotype in Finland, which also has a relatively isolated population and a high frequency of ALS and the *C9ORF72* expansion. The high frequency of expansions in apparently sporadic individuals is difficult to explain but is likely due to lack of family history information or previous generations dying early before the expansion caused disease. Another explanation is reduced penetrance of the expansion, and a further question is whether this pathogenic expansion goes through an intermediate expansion/anticipation phase as in other repeat expansion disorders such as Friedreich\'s ataxia ([@bib23]). Although we detected a small number of cases with 20--24 repeats (4/228 = 1.8%) in the control Greek population this frequency is not significantly different when compared with 2 UK control series (unpublished 1/85 = 1.2% and 6/361 = 1.7%).

In summary, we have shown that the pathogenic GGGGCC hexanucleotide repeat expansion in *C9ORF72* is an important cause of ALS in the Mediterranean Greek population in the familial and sporadic forms of disease. The frequency is high, second only to the Scandinavian population and this suggests the repeat prevalence in Greece, and likely in the Scandinavian countries is a consequence of population isolation and little racial admixture. The frequency also highlights the importance of establishing *C9ORF72* as a diagnostic test in familial and sporadic patients.
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Demographic and *C9ORF72* repeat data from the Greek ALS cases

                                 Total cohort   Familial      Sporadic      *p*                                       Expanded      Nonexpanded   Expanded (familial)   Expanded (sporadic)
  ------------------------------ -------------- ------------- ------------- ----------------------------------------- ------------- ------------- --------------------- ---------------------
  *n* (%)                        146            10 (6.8)      136 (93.2)                                              16 (11.0)     130 (89.0)    5 (50.0)              11 (8.1)
  Age as of 01/01/12 (y ± SD)    59.1 ± 13.0    50.8 ± 12.2   59.7 ± 12.9   0.035 [a](#tblfn1){ref-type="table-fn"}   56.4 ± 12.2   59.5 ± 13.1   57.2 ± 12.6           56.1 ± 12.6
  Male                           108 (74.0)     4 (40.0)      104 (76.5)    0.020 [b](#tblfn2){ref-type="table-fn"}   12 (75.0)     96 (73.8)     2 (40.0)              10 (90.9)
  Female                         38 (26.0)      6 (60.0)      32 (23.5)                                               4 (25.0)      34 (26.2)     3 (60.0)              1 (9.1)
  Age at onset of ALS (y ± SD)   57.3 ± 13.0    49.7 ± 11.1   57.9 ± 12.9   0.055[a](#tblfn1){ref-type="table-fn"}    55.1 ± 12.1   57.6 ± 13.1   55.6 ± 12.0           54.8 ± 12.7
  Mode of onset (%)                                                                                                                                                     
   Spinal                        106 (75.2)     10 (100.0)    96 (73.3)     0.067 [b](#tblfn2){ref-type="table-fn"}   13 (81.2)     93 (74.4)     5 (100.0)             8 (72.7)
   Bulbar                        35 (24.8)      0 (0.0)       35 (26.7)                                               3 (18.8)      32 (25.6)     0                     3 (27.3)
  *C9ORF72* repeat (%)                                                                                                                                                  
   Expanded                      16 (11.0)      5 (50.0)      11 (8.1)      0.002 [b](#tblfn2){ref-type="table-fn"}                                                     
   Nonexpanded                   130 (89.0)     5 (50.0)      125 (91.9)                                                                                                

Missing data from 5 sporadic patients.

Key: ALS, amyotrophic lateral sclerosis.

*t* test, familial versus sporadic.

Fisher exact test, 2-sided *p* value, familial versus sporadic; using a *t* test there was no significant difference seen between expanded versus nonexpanded age at onset.

[^1]: Equal contribution.
